---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-004229"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2022-03-21T23:59:59+00:00"
generated_at: "2026-06-26T21:29:22.576232+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Terns' TERN-201 Phase 1b AVIATION trial meets safety; no efficacy in NASH

## Summary
- Part 1 of Phase 1b AVIATION trial of TERN-201 10 mg met primary safety endpoint; well-tolerated with no SAEs.
- No meaningful changes in exploratory NASH biomarkers (cT1, ALT, AST, GGT, CK-18) vs placebo.
- Near complete (>98%) VAP-1 inhibition achieved but no efficacy signals.
- Part 2 (20 mg) ongoing; top-line results expected H2 2022.
- Cash runway into 2024; pipeline includes TERN-501 Phase 2a in H1 2022 and TERN-601 Phase 1 in 2023.

## SEC filing metadata
- accession: 0000950170-22-004229
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2022-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000095017022004229/0000950170-22-004229-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000095017022004229/tern-20220321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-004229
- JSON: https://secwatch.observer/filing/0000950170-22-004229.json
- Plain text: https://secwatch.observer/filing/0000950170-22-004229.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.